三种国产降压药治疗高血压的多中心研究  

Efficacy of domestic bisoprolol,enalapril and nifedipine retard in mild to moderate hypertension: a randomized double-blind multicenter clinical trial in China

作　　者：刘国树[1] 李鸣凤[1] 石湘芸[2] 李素芝[3] 郑开元[3] 郭勇梅 邹仁民 盖晓波[5] 马大波[6] 李志玫[7] 

机构地区：[1]解放军总医院,北京100853 [2]海军总医院 [3]成都军区西藏总医院 [4]北京军区机关门诊部 [5]南京军区福州总医院 [6]广州军区武汉总医院 [7]兰州军区乌鲁木齐总医院

出　　处：《中华内科杂志》2002年第7期450-453,共4页Chinese Journal of Internal Medicine

基　　金：军队"九五"医学科研课题基金资助项目 ( 96M14 4)

摘　　要：目的　比较三种国产降压药 (比索洛尔、依那普利、缓释硝苯地平 )对轻、中度高血压病患者的降压效果及耐受性。方法　 6个中心采用随机、双盲、组间平行对照法 ,将“九五军队高血压抽样队列调查”检出的轻、中度高血压病患者 331例分为比索洛尔组 (1 1 0例 ,5mg/d)、依那普利组 (1 1 1例 ,1 0mg/d)和缓释硝苯地平组 (1 1 0例 ,2 0mg/d) ,治疗 4周。以诊室血压为指标 ,比较 3种药物的降压疗效 ,并观察 3种药物对血糖、血脂、肝肾功能等的影响及不良反应。结果　国产比索洛尔、依那普利和缓释硝苯地平治疗轻、中度高血压病的总有效率分别为 :80 0 %、82 0 %、81 8% (P >0 0 5)。 3种药物不良反应发生率分别为 4 5 %、8 1 %、1 9 1 % (P <0 0 1 )。结论　 3种药物均有好的降压效果 ,组间比较差异无显著性。不良反应比索洛尔组最少 ,依那普利组次之 ,缓释硝苯地平组最多 ,均无严重不良反应 。Objective To compare the efficacy and tolerability of bisoprolol, enalapril and nifedipine retard in the treatment of mild to moderate essential hypertension Methods This is a randomized, double blind, multicenter clinical trial 331 patients with mild to moderate hypertension in the army troop were randomly allocated to receive domestic bisoprolol ( n =110,5 mg/d),enalapril ( n =111,10 mg/d) and nifedipine retard ( n =110,20 mg/day) Total duration of active drug treatment was 4 weeks Results The total efficacy rates of domestic bisoprolol, enalapril and nifedipine retard were 80 0%, 82 0% and 81 8% respectively( P >0 05) The incidences of adverse events were 4 5%, 8 1% and 19 1% ( P <0 01) in patients of bisoloprol, enalapril and nifedipine retard groups respectively The adverse effects were mild in all the three groups Conclusions Domestic bisoprolol, enalapril and nifedipine retard are effective and well tolerated in patients with mild to moderate essential hypertension The occurrence of adverse effects were least in the bisoprolol group and most in the nifedipine retard group

关 键 词：国产 降压药 治疗 高血压 多中心研究 比索洛尔 依那普利 缓释硝苯地平 

分 类 号：R544.1[医药卫生—心血管疾病] R972.4[医药卫生—内科学]